Skip to content
Fiscal Receipts

Chemical and Biological Defense (Operational Systems Development)

CBDPRDT&EPartial Reconciliation0607384BP
What it is
Chemical and Biological Defense (Operational Systems Development) (0607384BP) is a CBDP research & development line funded in the Research, Development, Test and Evaluation, Defense-Wide account. Its J-book detail breaks the line into 3 projects.
What changed
+$4.66M FY25→26 R-1 TOA · PB2026
Who gets it
No award linkage at high confidence.

Budget Figures

FY24 Actuals
$65.9MR-1 TOA · PB2026
FY25 Total
$74.5MR-1 TOA · PB2026
FY26 Request
$79.1MR-1 TOA · PB2026
FY25→26 Change
+$4.66MR-1 TOA · PB2026

FY2026 award data is a partial year — USASpending awards are reported on a rolling basis and the fiscal year does not close until September 30. why partial FY2026 data? →

Budget Trajectory
The program's 3 summary figures for FY24 to FY26, plotted in fiscal-year order so the direction of travel is readable at a glance: this line ends higher than it starts. The points are the summary cards above, not a separate derivation; the table beside the chart carries each figure with its own citation.
The program's 3 summary figures for FY24 to FY26, plotted in fiscal-year order so the direction of travel is readable at a glance: this line ends higher than it starts. The points are the summary cards above, not a separate derivation; the table beside the chart carries each figure with its own citation.FY24: $65.9MFY25: $74.5MFY26: $79.1MFY24FY25FY26
Budget trajectory: one row per fiscal year, carrying the summary figure the sparkline plots. Every figure opens its own citation.
Fiscal yearAmount
FY24$65.9M
FY25$74.5M
FY26$79.1M

All series figures: R-1 TOA · PB2026

Decade view — P-1/R-1 workbook TOA basis, shown compact in $B/$M (the workbook records USD thousands); each figure cites its own President's Budget edition
12 fiscal years of this program as published (FY2015–FY2026): a line through the actuals (filled dots), with the enacted (hollow circles) and request (diamonds) markers each edition reported. Read it for direction, not for precision — this program's actuals line rises across the span. The grid below is the same data as text, one cited figure per cell.
12 fiscal years of this program as published (FY2015–FY2026): a line through the actuals (filled dots), with the enacted (hollow circles) and request (diamonds) markers each edition reported. Read it for direction, not for precision — this program's actuals line rises across the span. The grid below is the same data as text, one cited figure per cell.FY2015 actuals — PB2017 editionFY2016 actuals — PB2018 editionFY2017 actuals — PB2019 editionFY2018 actuals — PB2020 editionFY2019 actuals — PB2021 editionFY2020 actuals — PB2022 editionFY2021 actuals — PB2023 editionFY2022 actuals — PB2024 editionFY2023 actuals — PB2025 editionFY2024 actuals — PB2026 editionFY2016 enacted — PB2017 editionFY2017 enacted — PB2018 editionFY2018 enacted — PB2019 editionFY2019 enacted — PB2020 editionFY2020 enacted — PB2021 editionFY2021 enacted — PB2022 editionFY2022 enacted — PB2023 editionFY2023 enacted — PB2024 editionFY2024 enacted — PB2025 editionFY2025 enacted — PB2026 editionFY2017 request — PB2017 editionFY2018 request — PB2018 editionFY2019 request — PB2019 editionFY2020 request — PB2020 editionFY2021 request — PB2021 editionFY2022 request — PB2022 editionFY2023 request — PB2023 editionFY2024 request — PB2024 editionFY2025 request — PB2025 editionFY2026 request — PB2026 editionFY15FY18FY20FY22FY24FY26

The vertical scale does not start at zero: the baseline sits just below this program’s smallest year, so a low point on this line is not a small amount. Read the shape for direction and the grid below for the figures.

● actuals (line)  ·  ○ enacted  ·  ◇ request — gaps are editions the program is absent from, never interpolated.

Decade series values by fiscal year and President's Budget edition: one row per series (actuals, enacted, request), one column per fiscal year. Every figure opens its own citation.
SeriesFY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Actuals$28.1M$28.3M$32.2M$43.6M$41.8M$50.7M$38.5M$55.4M$64.2M$65.9M
Enacted$33.6M$33.4M$45.7M$43.7M$51.8M$39.5M$58.3M$65.6M$80.5M$74.5M
Request$33.4M$45.7M$48.7M$54.0M$39.5M$58.3M$68.0M$80.5M$84.1M$79.1M

blank = series not published for this year; – = absent from that edition.

Asked vs spent: the PB2024 book requested $80.5M for FY2024; the PB2026 book reported $65.9M as actual total obligation authority — $14.6M below the request. 65.980.5 = -14.6 USD millions — the compact figures above are rounded for reading.

Program Lineage

No predecessor/successor lineage was recorded for this program element — no FY-to-FY transfer into or out of this line was stated in the ingested J-books, and none was inferred from the program structure.

Description

Mission Chemical and Biological Defense (Operational Systems Development)

This program element (PE) resources Operational System Development across the Understand, Protect, and Mitigate portfolios. Chemical and Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable Department of Defense (DoD) missions in a chemical and biological environment, ranging from combat operations to domestic incident prevention and response. The Projects in this PE support the upgrade of systems that have been fielded or have received approval for full-rate production in order to maintain Joint Force readiness. Individual Projects include: - Understand (UN7): Modernization and ongoing engineering of software and information systems. Continued development and testing of CB sensor equipment to ensure interoperability with emerging information technology and reduce size, weight, and power requirements, thereby easing logistical burdens. Refresh fielded medical diagnostic systems and capabilities, such as assays, to strengthen defenses against biological warfare agents. Upgrade medical nerve agent treatment systems to enhance defenses against chemical warfare threats facing U.S. Forces. - Protect (PT7): Efforts to refresh technology of fielded individual and protective equipment that enables the Joint Force to operate in a contaminated chemical and biological (CB) environment with little or no degradation of performance. Technology refresh efforts for fielded collective protection systems that are smaller, lighter, less costly to produce and maintain, and more logistically supportable, enabling mission accomplishment in spaces safe from the effects of CB contamination. - Mitigate (MT7): Technology refresh of fielded Contamination Mitigation systems that will remove and/or detoxify contaminated material without damaging combat equipment, personnel, or the environment. The projects in this PE support operational systems development necessary to maintain operational effectiveness and are, therefore, correctly placed in Budget Activity 7.

Mission Mitigate (Op Sys Dev)

The Mitigate Operational System Development Project provides the Joint Force continued readiness of fielded personnel and materiel contamination mitigation and chemical agent therapeutic capabilities and provides size, weight and power improvements to reduce logistical burden on the warfighter. Efforts included in this Project are: (1) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP) (2) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Pyridostigmine Bromide Extended Release (PB ER) (3) Modernization Protection Decontamination (MODPROT DE) (4) Modernization Hazard Mitigation (MOD HM)

Mission Protect (Op Sys Dev)

The Protect Operational System Development Project provides the Joint Force the continued readiness of fielded collective and individual protective capabilities and provides size, weight and power improvements to reduce logistical burden on the warfighter and services. Efforts included in this Project are: (1) Modernization Protection Collective Protection (MODPROT CP) (2) Modernization Protection Individual Protection (MODPROT IP)

Mission Understand (Op Sys Dev)

The Understand Operational System Development Project provides the Joint Force continued readiness of fielded sensor, information technology and medical diagnostic capabilities and provides size, weight and power improvements to reduce logistical burden on the warfighter and services. Efforts included in this Project are: (1) Chemical Biological Radiological Nuclear Support to Command and Control (CSC2) (2) Modernization Sensors (MOD SEN) (3) Modernization Medical (MOD MED) - NGDS 1 Tech Refresh (4) Modernization Medical (MOD MED) - Diagnostic System Upgrades / Assay Development (5) Modernization Medical (MOD MED) - Autoinjector Post Marketing Commitments and Requirements (PMRs/PMCs) (6) Modernization Medical (MOD MED) - Fielded System Improvements and Post-Fielding Requirements (7) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) - System Modernization (8) Weapons of Mass Destruction - Civil Support Team (WMD CST)

Justification

Accomplishments & Planned Programs (14)

1) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP)

The INATS CA program will develop the centrally acting anticholinergic, scopolamine, to increase survivability and decrease morbidity following exposure to toxic nerve agents. INATS CA benefits the warfighter by adding current fielded nerve agent treatments such as scopolamine and pyridostigmine bromide which will improve overall medical outcomes.

2) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - PB ER

Pyridostigmine Bromide (PB) Extended Release (ER) Tablet Development

3) Modernization Protection Decontamination (MODPROT DE)

The MODPROT DE effort addresses modernization and obsolescence across the Department of Defense (DoD) Hazard Mitigation portfolio to increase readiness, sustainability, reliability, and affordability of these systems. MODPROT DE supports the Joint Service Transportable Decon System – Small Scale (JBTDS-SS), Power Driven Decontamination Apparatus (PDDA), Decontamination Family of Systems General Purpose Decontaminant (DFoS GPD), M295 Decontamination Kit, and M100 Sorbent Decontamination System (SDS) programs. MODPROT DE benefits the warfighter by addressing obsolescence of critical equipment, assessment of currently fielded systems against current priority threats, and conducting real time shelf-life studies. This project is funded in FY 2025 and beyond under Modernization Hazard Mitigation (MOD HM) and was renamed MOD HM to accurately reflect the capability and applicability of the system.

4) Modernization Hazard Mitigation (MOD HM)

The MOD HM effort addresses modernization and obsolescence across the Department of Defense (DoD) HM portfolio to increase readiness, sustainability, reliability, and affordability of these systems. MOD HM supports the Joint Service Transportable Decon System – Small Scale (JSTDS-SS), Power Driven Decontamination Apparatus (PDDA), Decontamination Family of Systems General Purpose Decontaminant (DFoS GPD), M295 Decontamination Kit, and M100 Sorbent Decontamination System (SDS) programs. MOD HM benefits the warfighter by addressing obsolescence of critical equipment, assessment of currently fielded systems against current priority threats, and conducting real time shelf-life studies. This project was funded in FY 2024 under Modernization Decontamination (MODPROT DE) and was renamed MOD HM to accurately reflect the capability and applicability of the system.

1) Modernization Protection Collective Protection (MODPROT CP)

The MODPROT CP effort addresses modernization and obsolescence across the Department of Defense (DoD) Collective Protection (CP) portfolio to increase readiness, sustainability, reliability, and affordability of these systems. MODPROT CP modernizes decades old collective protection equipment reducing costs, shortening lead times, and updating key components to extend service life and ensure affordable and procurable to warfighters. MODPROT CP will conduct system filter surveillance testing to improve system sustainment, develop a design guide for ground vehicle platforms, modernize mobile platform filters, modernize ship platform filtration systems, modernize liners and closures for collective protection shelters, and explore new filter media technology transitions. MODPROT CP supports the modernization of CP ships and buildings. MODPROT CP benefits the warfighter by addressing obsolescence of critical equipment, assessment of currently fielded systems against current priority threats, and conducting real time shelf-life studies.

2) Modernization Protection Individual Protection (MODPROT IP)

MODPROT IP addresses modernization and obsolescence across the Department of Defense (DoD) Individual Protection (IP) portfolio to increase readiness, sustainability, reliability, and affordability of these systems. MODPROT IP reduces logistics costs and obsolescence issues with individual protection percutaneous and respiratory/ocular equipment, to include test equipment, and the need to modernize the Joint Services fielded Chemical and Biological protection with capabilities meeting or exceeding the Services requirements. MODPROT IP supports the Joint Mask Leakage Tester (JSMLT), Fixed Wing Aircraft/Aircrew Personal Protective Equipment (PPE), Individual Protective Equipment (IPE) products, Chemical and Biological Response Enterprise Personal Protective Equipment (CRE PPE), and Joint Service Lightweight Integrated Suit Technology (JSLIST). MODPROT IP benefits the warfighter by addressing obsolescence of critical equipment, assessment of currently fielded systems against current priority threats, and conducting real time shelf-life studies.

1) Chemical Biological Radiological Nuclear Support to Command and Control (CSC2)

Continuous engineering for the currently deployed chemical and biological (CB) information systems (Joint Effects Model (JEM), Joint Warning and Reporting Network (JWARN), Chemical, Biological, Radiological, Nuclear (CBRN) Information System (CBRN IS)), and CSC2. Effort encompasses the processes, procedures, people, material and information required to support and modernize fielded CB information systems and applications. CB Warning Reporting and Hazard Prediction capabilities and efforts will be transitioned to CSC2 in the FY 2027- FY 2029 timeframe. The approach to consolidation simplifies software BA7 management under one line and synchronizes the sunset of JEM and JWARN systems as replacement capabilities are deployed through CSC2.

2) Modernization Sensors (MOD SEN)

MOD SEN performs technology refresh, modernization and continuous engineering of equipment and software to shape and inform the battlespace against chemical and biological threats. MOD SEN conducts development and testing of chemical and biological sensor equipment to address obsolescence of critical equipment and functionality issues for the Services to decrease size, weight, and power requirements, reduce logistical burden, and maintain interoperability of capabilities. MOD SEN supports the Analytical Laboratory System Modification (ALS MOD), Common Analytical Laboratory System (CALS) Field Confirmatory Analytical Capability Set (FC ACS), CALS Theater Validation Integrated System (TV IS), Chemical Biological Radiological Nuclear Dismounted Reconnaissance System (CBRN DRS), Joint Chemical Agent Detector (JCAD) M4A1, M8 Chemical Detection Paper, and Enhanced Maritime Biological Detection (EMBD) programs. MOD SEN benefits the warfighter by establishing a time phased modernization plan to address equipment obsolescence, system functionality improvements, and integrate technological advancements.

3) Modernization Medical (MOD MED) - NGDS 1 Tech Refresh

The MOD MED program supports improvements to fielded systems and supports post-fielding U.S. Food & Drug Administration (FDA) requirements for Chemical and Biological (CB) Medical devices, including FDA-approved autoinjectors and diagnostic equipment, in order to mitigate obsolescence and maintain fielded capabilities. The MOD MED Next Generation Diagnostics System 1 Tech Refresh program benefits the warfighter by modernizing medical countermeasures through developmental engineering efforts to sustain a critical diagnostic capability.

4) Modernization Medical (MOD MED) - Diagnostic System Upgrades / Assay Development

The MOD MED program supports improvements to fielded systems and supports post-fielding U.S. Food & Drug Administration (FDA) requirements for Chemical and Biological (CB) Medical devices, including FDA-approved autoinjectors and diagnostic equipment, in order to mitigate obsolescence and maintain fielded capabilities. The MOD MED Diagnostic System Upgrades / Assay Development program benefits the warfighter by maintaining fielded diagnostic capabilities to sustain technologies and address emerging threats.

5) Modernization Medical (MOD MED) - Autoinjector Post Marketing Commitments and Requirements (PMRs/PMCs)

The MOD MED program supports improvements to fielded systems and supports post-fielding U.S. Food & Drug Administration (FDA) requirements for Chemical and Biological (CB) Medical devices, including FDA-approved autoinjectors and diagnostic equipment, in order to mitigate obsolescence and maintain fielded capabilities. The MOD MED Autoinjector Post Marketing Commitments and Requirements (PMRs/PMCs) program benefits the warfighter by maintaining fielded autoinjector capabilities.

6) Modernization Medical (MOD MED) - Fielded System Improvements and Post-Fielding Requirements

MOD MED supports improvements to fielded systems and products and supports post-fielding Food & Drug Administration (FDA) requirements for Chemical and Biological (CB) medical devices and treatments; efforts include FDA-approved autoinjectors, diagnostic equipment, and treatments in order to mitigate obsolescence and maintain fielded capabilities. It exploits new and emerging FDA-compliant technologies and updated manufacturing guidelines, supports FDA-required post-marketing commitments (PMCs) and post-marketing requirements (PMRs), and continually mitigates cybersecurity risks. MOD MED benefits the warfighter by preventing premature capability loss through maintenance of cybersecurity controls and FDA compliance, refreshing obsolescing capabilities, and executing preplanned product improvements to fielded platforms.

7) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) - System Modernization

SPU RCDD facilitates United States Special Operations Command (USSOCOM) rapid response requirements, through the classified special category (SPECAT) process, for near-term and emergent chemical-biological defensive capabilities. SPU RCDD mitigates risk across the Enterprise by creating a portfolio of operationally relevant chemical and biological defense capabilities that can be quickly transitioned in response to the articulated, developing capability needs of the geographic combatant commanders. These objectives are met by the early transitioning of promising science and technology (S&T); the focused conduct of combat evaluations and mission-oriented operational assessments to assess technological and mission suitability; and leveraging existing Commercial-Off-The-Shelf (COTS) and Government-Off-The-Shelf (GOTS) products along with novel redesign approaches to optimize existing solutions to new challenges supported by adaptive acquisition strategies.

8) Weapons of Mass Destruction Civil Support Teams (WMD CST)

The Weapons of Mass Destruction Civil Support Teams (WMD CST) supports the fielded system upgrade and ongoing assessment and acquisition of Commercial Off-the-Shelf (COTS) and Government Off-the-Shelf (GOTS) analytical detection, protection, decontamination and sampling equipment for survey in order to expand/enhance the operational capabilities of the WMD CST. WMD CST benefits the warfighter by actively monitoring the currently fielded National Guard Bureau (NGB) equipment and establishes a time phased modernization roadmaps to integrate and incorporate proven advancements in commercially available technology into the NGB mission set based on highest priority capability requirements and availability of resources.

Budget Line Items(workbook-cited)

P-1/R-1 workbook Total Obligation Authority basis (USD thousands) · PB2026.

Exhibit R-1

AccountOrgTypeAmount
Research, Development, Test and Evaluation, Defense-WideCBDPFY24 Actuals$65.9M
Research, Development, Test and Evaluation, Defense-WideCBDPFY25 Enacted$74.5M
Research, Development, Test and Evaluation, Defense-WideCBDPFY25 Total$74.5M
Research, Development, Test and Evaluation, Defense-WideCBDPFY26 Disc. Request$79.1M
Research, Development, Test and Evaluation, Defense-WideCBDPFY26 Total$79.1M

Budget Details(R-2/P-40 facts)

J-book detail basis (R-2/P-40, USD millions) · PB2026 — a different accounting basis from the P-1/R-1 workbook TOA above; where the two disagree, the reconciliation strip under Budget Figures shows both.

Wider than this screen — swipe the table sideways for the remaining fiscal-year columns.

ProjectAll Prior YearsFY24 ActualsFY25 TotalFY26 BaseFY26 Request
Program Element$0$65.9M$74.5M$79.1M$79.1M
MT7: Mitigate (Op Sys Dev)$2.37M$1.09M$1.03M$1.03M
PT7: Protect (Op Sys Dev)$24.0M$21.8M$15.6M$15.6M
UN7: Understand (Op Sys Dev)$39.5M$51.6M$62.5M$62.5M

No follow-the-dollar view — this program's awards haven't been crosswalked at high confidence (flows cover 17 of 1,741 programs). why coverage is partial? →

Awards

No awards are linked to this program element at high confidence — the budget→award crosswalk only asserts links it can defend, and this line has none yet.

Lobbying Mentions

No Senate LDA lobbying filing in the tracked data mentions this program element by code or alias.

Oversight

Department-level designation (not specific to this program)

GAO lists 5 high-risk areas for DOD as a whole. That designation covers the department, not Chemical and Biological Defense (Operational Systems Development) — no program-specific GAO finding for this line is in the ingested data. See the DOD oversight record.

No research dossier for this program — dossiers cover 50 of 1,741 programs, the largest fully J-book-detailed lines by FY2026 requested dollars. why no dossier here? →